P
Peter J Trainer
Researcher at Manchester Academic Health Science Centre
Publications - 228
Citations - 13428
Peter J Trainer is an academic researcher from Manchester Academic Health Science Centre. The author has contributed to research in topics: Acromegaly & Pegvisomant. The author has an hindex of 50, co-authored 225 publications receiving 12353 citations. Previous affiliations of Peter J Trainer include St Bartholomew's Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
The Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
TL;DR: A differential diagnosis of ACTH-Dependent Cushing’s Syndrome and differentiation from Pseudo-Cushing”s States are presented.
Journal ArticleDOI
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Peter J Trainer,W. M. Drake,Laurence Katznelson,Pamela U. Freda,Herman-Bonert,van der Lely Aj,Eleni V. Dimaraki,Paul M. Stewart,K. E. Friend,Mary Lee Vance,G. M. Besser,John A. Scarlett,Michael O. Thorner,Craig Parkinson,Anne Klibanski,Powell Js,Ariel L. Barkan,Michael C. Sheppard,Malsonado M,Rose Dr,David R. Clemmons,Gudmundur Johannsson,B.-Å. Bengtsson,Stavros Stavrou,David L. Kleinberg,David M. Cook,Lawrence S. Phillips,Martin Bidlingmaier,Christian J. Strasburger,Hackett S,Kenneth A. Zib,Bennett Wf,Robert J. Davis +32 more
TL;DR: Treatment of patients who have acromegaly with pegvisomant with a growth hormone–receptor antagonist results in a reduction in serum IGF-I concentrations and in clinical improvement.
Journal ArticleDOI
A Consensus on Criteria for Cure of Acromegaly
Andrea Giustina,Philippe Chanson,Marcello D. Bronstein,Anne Klibanski,Steven W. J. Lamberts,Felipe F. Casanueva,Peter J Trainer,Ezio Ghigo,Ken K. Y. Ho,Shlomo Melmed +9 more
TL;DR: Criteria to define active acromegaly and disease control were agreed, and several significant changes were made to the 2000 guidelines.
Journal ArticleDOI
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
Aart Jan van der Lely,R. Kent Hutson,Peter J Trainer,G. Michael Besser,Ariel L. Barkan,Laurence Katznelson,Anne Klibanski,Vivien Herman-Bonert,Shlomo Melmed,Mary Lee Vance,Pamela U. Freda,Paul M Stewart,Keith E Friend,David R. Clemmons,Gudmundur Johannsson,Stavros Stavrou,David M. Cook,Lawrence S. Phillips,Christian J. Strasburger,Suzanne Hacker,Kenneth A. Zib,Robert J. Davis,John A. Scarlett,Michael O. Thorner +23 more
TL;DR: Pegvisomant is an effective medical treatment for acromegaly and of the patients treated for 12 months or more, 87 of 90 (97%) achieved a normal serum IGF-1 concentration.
Journal ArticleDOI
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly
TL;DR: Clinical trials in patients with acromegaly show GHR blockade to be an exciting new mode of therapy for this condition, and pegvisomant may have a therapeutic role in diseases, such as diabetes and malignancy, in which abnormalities of the GH/IGF-I axis have been observed.